Use of Synthetic Antibodies Targeted to the Jak/Stat Pathway in Breast Cancer
Abstract
This proposal seeks to generate sABs (synthetic antigen binders) against the PRLr (prolactin receptor)signaling complex to systematically inhibit and modulate its important activities in breast cancer. This complex has clearly been demonstrated to play a significant role in development and spread of this disease, and yet the generation of pharmacologic agents that can specifically block their function has been slow. We hypothesize that sABs can be generated to the PRLr, CypA, and CypB proteins and delivered into the cell, where these reagents will block breast cancer growth, survival and spread. We have successfully generated sABs to CypA and B and the extracellular domain of PRLr and have begun their characterization. It is the intent of this proposal to validate the efficacy of these highly innovative reagents on a panel of breast cancer cells in vitro, with future translation into pre-clinical testing.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2010
- Accession Number
- ADA552192
Entities
People
- Anthony A. Kossiakoff
Organizations
- University of Chicago